Skip navigation.

Welcome to SAfAIDS

SAfAIDS news

Africa: Daily pill should be part of a combined approach to preventing HIV

A 'magical' pill, popularly known as Truvada, emerged in the HIV community a few years ago but is continuing to cause controversy. This pill (emtricitabine and tenofovir disoproxil fumarate) was approved as an HIV infection risk inhibitor and was intended for people who engage in high risk sexual behavior. Studies have shown it reduces the risk of HIV infection by 90 per cent.

Spotlight: Harare Treats 120 000 HIV-Related Cases a Day

HARARE, 13 November 2014 (Herald) - HARARE City Council says 120 000 residents are treated for HIV related ailments in the city everyday. According to minutes of a full council meeting, the rate of infections is increasing. "On AIDS statistics, council was advised that the prevalence at the national level is at 15 percent and in Harare the prevalence is at 13 percent.

Zimbabwe: Stigmatization of University Pregnancies Negatively Affecting Female Students

HARARE, 13 November 2014 (Zimbabwe Sentinel) - The infanticide case of a first year student Thelma Rumbidzai Mupatsi at Chinhoyi University of Technology is an indication of numerous social economic challenges faced by students in tertiary institutions local health organisations have said.


Look at behavior economics to improve ART adherence

PHILADELPHIA, 13 November 2014 - Making HIV medications free or low cost is very important for removing barriers to HIV care access, but it’s not enough to ensure adherence, Kevin Volpp said at IDWeek. HIV/AIDS programs must take behavioral economics into account when designing programs to promote adherence and ensure people living with HIV remain in the cascade of care.

South Africa: HIV infection highest among men who have sex with men

DURBAN, 12 November 2014 (aidsmap) - Almost half of the men who have sex with men in Durban are HIV infected and about a quarter of such men in Johannesburg and Cape Town have HIV, according to a Human Sciences Research Council (HSRC) study that was released on Tuesday.


Targeted adherence measures and viral load monitoring needed to improve retention in South African ART programme

JOHANNESBURG, 12 November 2014 (aidsmap) - Of the people living with HIV in South Africa who are eligible to start antiretroviral therapy (ART), only 57% are in care and only 37% of the 2012/2013 cohort of people receiving ART were given a viral load test, according to new results announced by the CEO of the South African National AIDS Council (SANAC) at the Southern African HIV Clinicians Society Conference held in Cape Town, South Africa, last month.


Syndicate content